PL2121025T3 - Sposoby i kompozycje dla dostarczania czynnika terapeutycznego - Google Patents

Sposoby i kompozycje dla dostarczania czynnika terapeutycznego

Info

Publication number
PL2121025T3
PL2121025T3 PL08705994T PL08705994T PL2121025T3 PL 2121025 T3 PL2121025 T3 PL 2121025T3 PL 08705994 T PL08705994 T PL 08705994T PL 08705994 T PL08705994 T PL 08705994T PL 2121025 T3 PL2121025 T3 PL 2121025T3
Authority
PL
Poland
Prior art keywords
delivery
compositions
methods
therapeutic agent
therapeutic
Prior art date
Application number
PL08705994T
Other languages
English (en)
Polish (pl)
Inventor
Sveinbjorn Gizurarson
James Arp
Raouf Ghaderi
Michael E. Lusty
Gregory G. Plucinski
Mehdi Yazdi
Original Assignee
Hananja Ehf
University Of Iceland
Ikano Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hananja Ehf, University Of Iceland, Ikano Therapeutics Inc. filed Critical Hananja Ehf
Publication of PL2121025T3 publication Critical patent/PL2121025T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08705994T 2007-01-19 2008-01-18 Sposoby i kompozycje dla dostarczania czynnika terapeutycznego PL2121025T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IS8593 2007-01-19

Publications (1)

Publication Number Publication Date
PL2121025T3 true PL2121025T3 (pl) 2017-09-29

Family

ID=39512543

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08705994T PL2121025T3 (pl) 2007-01-19 2008-01-18 Sposoby i kompozycje dla dostarczania czynnika terapeutycznego

Country Status (11)

Country Link
EP (2) EP2121025B1 (enExample)
JP (5) JP5877939B2 (enExample)
CN (3) CN101678112B (enExample)
AU (1) AU2008206105B2 (enExample)
CA (1) CA2676010C (enExample)
DK (1) DK2121025T3 (enExample)
ES (1) ES2611995T3 (enExample)
HU (1) HUE031463T2 (enExample)
IL (1) IL199904A (enExample)
PL (1) PL2121025T3 (enExample)
WO (1) WO2008089426A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
GB2481407B (en) * 2010-06-22 2012-05-23 Special Products Ltd A rapid onset liquid midazolam composition for buccal administration
HRP20180233T1 (hr) * 2011-05-13 2018-06-01 Euro-Celtique S.A. Intranazalni farmaceutski oblici doziranja koji sadrže nalokson
CN111278425B (zh) 2017-09-11 2024-06-11 耶路撒冷希伯来大学伊萨姆研究开发有限公司 用于向脑部经鼻给药药物和用于全身作用的组合物和方法
JP2019099557A (ja) * 2017-11-28 2019-06-24 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
WO2019226753A1 (en) 2018-05-25 2019-11-28 Ucb Biopharma Sprl Benzodiazepine formulations
CN111388481A (zh) * 2020-03-20 2020-07-10 浙江美华鼎昌医药科技有限公司 一种咪达唑仑和丙戊酸钠的药物组合物及其制备方法
CN114588116B (zh) * 2020-12-04 2024-03-15 四川科瑞德制药股份有限公司 磷苯妥英钠固体组合物、冻干方法、及其用途
CN113274482B (zh) * 2021-06-07 2023-09-05 穆琳 缩宫素或其衍生物在制备治疗或改善贫乳的制剂中的用途以及组合物
US20260199340A1 (en) * 2022-12-26 2026-07-16 Cipla Limited Stable aqueous injectable formulation of flucytosine
CN119488471A (zh) * 2023-08-17 2025-02-21 纳索菲德(上海)制药技术有限公司 一种尼莫地平鼻脑递释制剂、其制备方法及其用途
WO2025115019A1 (en) * 2023-11-30 2025-06-05 Padagis Israel Pharmaceuticals Ltd. Stable nitroglycerin formulations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153689A (en) 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
JP2573275B2 (ja) * 1986-03-10 1997-01-22 ブルグハルト,クルト 薬学的製剤及びその製造法
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
DK0532546T3 (da) 1990-05-10 1998-12-28 Nycomed Pharma As Farmaceutisk præparat indeholdende N-glycofuroler og N-ethylenglycoler
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
GB9125699D0 (en) 1991-12-03 1992-01-29 Glaxo Group Ltd Device
US5897880A (en) * 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
BR9710130A (pt) * 1996-07-03 1999-08-10 Alza Corp Formulações de peptídeos próticas não-aquosas
CA2379365C (en) * 1999-07-26 2009-11-17 Sk Corporation Transnasal anticonvulsive compositions and modulated process
KR100360827B1 (ko) * 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
DE19940236A1 (de) 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
US20020037319A1 (en) * 1999-11-08 2002-03-28 Alan Drizen Drug preparations
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
JP2004505730A (ja) 2000-08-15 2004-02-26 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション プログラム可能多用量鼻腔内薬物送達デバイス
CA2486909A1 (en) * 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Kdl株式会社 ピリドン誘導体の溶液状医薬組成物
JP2007070225A (ja) * 2003-07-25 2007-03-22 Yukako Fujinaga クロストリジウム属菌由来成分を含む医薬製剤
WO2005027977A2 (en) * 2003-09-22 2005-03-31 Agis Industries (1983) Ltd. Diclofenac compositions for the treatment of skin disorders
JP2007510733A (ja) * 2003-11-05 2007-04-26 サンタラス インコーポレイティッド プロトンポンプ阻害剤および睡眠剤の併用
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
JP4746856B2 (ja) * 2004-08-12 2011-08-10 三笠製薬株式会社 ピラゾロン系製剤
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
PL1848403T3 (pl) * 2005-01-14 2010-09-30 Camurus Ab Preparaty bioadhezyjne o działaniu miejscowym
US20070021411A1 (en) * 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
WO2008063634A1 (en) * 2006-11-21 2008-05-29 Novartis Ag Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure

Also Published As

Publication number Publication date
IL199904A (en) 2014-07-31
JP2017048250A (ja) 2017-03-09
EP2121025B1 (en) 2016-11-02
EP3150230A1 (en) 2017-04-05
JP6295314B2 (ja) 2018-03-14
WO2008089426A3 (en) 2009-02-12
JP6084277B2 (ja) 2017-02-22
AU2008206105B2 (en) 2014-04-03
ES2611995T3 (es) 2017-05-11
CN106389330A (zh) 2017-02-15
CN106420614A (zh) 2017-02-22
JP2017155060A (ja) 2017-09-07
JP2016029117A (ja) 2016-03-03
CN101678112A (zh) 2010-03-24
JP2010516696A (ja) 2010-05-20
AU2008206105A1 (en) 2008-07-24
CA2676010C (en) 2016-05-17
EP2121025A2 (en) 2009-11-25
JP5877939B2 (ja) 2016-03-08
JP2013231089A (ja) 2013-11-14
HUE031463T2 (en) 2017-07-28
DK2121025T3 (en) 2017-01-30
CA2676010A1 (en) 2008-07-24
IL199904A0 (en) 2010-04-15
WO2008089426A2 (en) 2008-07-24
CN101678112B (zh) 2016-08-31

Similar Documents

Publication Publication Date Title
AP2965A (en) Therapeutic compositions and the use thereof
AP2490A (en) Therapeutic compositions and the use thereof
ZA200904936B (en) Benefit agent delivery compositions
IL202684A0 (en) Anti-cd20 therapeutic compositions and methods of use thereof
EP2180873A4 (en) THERAPEUTIC DENTAL COMPOSITION AND RELATED METHODS
IL207569A0 (en) Compositions and methods for drug delivery
EP2101855A4 (en) ADMINISTRATION OF ANTI-THERAPY
GB0625659D0 (en) Therapeutic compounds and their use
GB0609492D0 (en) Therapeutic agents
SI2343982T1 (sl) Farmacevtski sestavki in metode povezane z dostavo
GB0608928D0 (en) Therapeutic agents
GB0601962D0 (en) Therapeutic agents
IL195764A0 (en) Compositions and methods for drug delivery
EP2010162A4 (en) COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
IL198723A0 (en) Methods and compositions for therapeutic treatment
IL197235A0 (en) Therapeutic compositions
IL199904A0 (en) Compositions comprising a therapeutic agent and an alkoxy-polyethylene glycol and uses thereof
GB0616214D0 (en) Therapeutic Agents
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
EP2236148A4 (en) MEDIinic agent for HELICOBACTER treatment
GB0611152D0 (en) Therapeutic agents
GB0620059D0 (en) Therapeutic agents
PL2236145T3 (pl) Kompozycja farmaceutyczna i lek złożony
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE